Revista espanola de enfermedades digestivas · 2025
Assessing inflammatory bowel disease monitoring procedures in Spain: insights from the IBD-PODCAST study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huguet José María, Gómez Delgado Elena, Rubio Saioa, Suárez Álvarez Patricia, Vera Mendoza Isabel, Paredes José María, Hernández Camba Alejandro, Plaza Santos Rocío, Mañosa Míriam, Pajares Villarroya Ramón, Madero Velázquez Lucía, Vega Pablo, Santos de Lamadrid Regina, Michelena Naiara, García Miriam, Gomollón Fernando
Аннотация
INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) are characterized by persistent gastrointestinal inflammation. Timely, effective management is crucial to improve long-term patient outcomes.
MATERIALS AND METHODS: as part of the IBD-PODCAST study, this cross-sectional, multicenter, non-interventional study included 396 patients (196 CD, 200 UC) from 14 Spanish hospitals, aiming to assess treat-to-target implementation through monitoring practices in a real-world setting. Biochemical markers (C-reactive protein [CRP], fecal calprotectin [fCal]) measured within ± 14 days of index date and imaging tests (endoscopy, intestinal ultrasound [IUS], magnetic resonance imaging/magnetic resonance enterography/computed tomography [MRI/MRE/CT]) during the previous year were collected. Actions taken based on the results were evaluated.
RESULTS: biochemical markers were requested in more than half the patients and imaging in a third, including endoscopic procedures in 18.9 % of CD and 28 % of UC cases, and IUS in < 12 % of patients. Treatment was adjusted in 67 % of CD patients with symptoms and 67 % of UC patients with rectal bleeding. Only 39 % of CD and 26 % of UC patients with abnormal fCal had treatment modifications, with 35 % and 37 % undergoing additional monitoring, respectively. Endoscopic findings prompted adjustments in 87 % of CD and 56 % of UC patients.
CONCLUSION: the IBD-PODCAST study examined routine IBD management in Spain, highlighting the need for improved monitoring and intervention to optimize patient care and outcomes.
MATERIALS AND METHODS: as part of the IBD-PODCAST study, this cross-sectional, multicenter, non-interventional study included 396 patients (196 CD, 200 UC) from 14 Spanish hospitals, aiming to assess treat-to-target implementation through monitoring practices in a real-world setting. Biochemical markers (C-reactive protein [CRP], fecal calprotectin [fCal]) measured within ± 14 days of index date and imaging tests (endoscopy, intestinal ultrasound [IUS], magnetic resonance imaging/magnetic resonance enterography/computed tomography [MRI/MRE/CT]) during the previous year were collected. Actions taken based on the results were evaluated.
RESULTS: biochemical markers were requested in more than half the patients and imaging in a third, including endoscopic procedures in 18.9 % of CD and 28 % of UC cases, and IUS in < 12 % of patients. Treatment was adjusted in 67 % of CD patients with symptoms and 67 % of UC patients with rectal bleeding. Only 39 % of CD and 26 % of UC patients with abnormal fCal had treatment modifications, with 35 % and 37 % undergoing additional monitoring, respectively. Endoscopic findings prompted adjustments in 87 % of CD and 56 % of UC patients.
CONCLUSION: the IBD-PODCAST study examined routine IBD management in Spain, highlighting the need for improved monitoring and intervention to optimize patient care and outcomes.